To include your compound in the COVID-19 Resource Center, submit it here.

MDX-33: Phase II

MEDX and partner Aventis Behring L.L.C. (King of Prussia, Penn.) said that in a

Read the full 146 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE